Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Nadia A. Khalil, Eman M. Ahmed, Ashraf F. Zaher, Eman A. Sobh, Samiha A. El-Sebaey & Mona S. El-Zoghbi. (2021) New benzothieno[2,3-c]pyridines as non-steroidal CYP17 inhibitors: design, synthesis, anticancer screening, apoptosis induction, and in silico ADME profile studies. Journal of Enzyme Inhibition and Medicinal Chemistry 36:1, pages 1839-1859.
Read now
Read now
Mohamad Moussa, Athanasios Papatsoris, Mohamed Abou Chakra, Despoina Sryropoulou & Athanasios Dellis. (2020) Pharmacotherapeutic strategies for castrate-resistant prostate cancer. Expert Opinion on Pharmacotherapy 21:12, pages 1431-1448.
Read now
Read now
Athanasios E. Dellis & Athanasios G. Papatsoris. (2019) Perspectives on the current and emerging chemical androgen receptor antagonists for the treatment of prostate cancer. Expert Opinion on Pharmacotherapy 20:2, pages 163-172.
Read now
Read now
Athanasios E. Dellis & Athanasios G. Papatsoris. (2018) Apalutamide: the established and emerging roles in the treatment of advanced prostate cancer. Expert Opinion on Investigational Drugs 27:6, pages 553-559.
Read now
Read now
Fable Zustovich & Davide Pastorelli. (2016) Therapeutic management of bone metastasis in prostate cancer: an update. Expert Review of Anticancer Therapy 16:11, pages 1199-1211.
Read now
Read now
Articles from other publishers (8)
Chetan Padmakar Darne, Upender Velaparthi, Mark Saulnier, David Frennesson, Peiying Liu, Audris Huang, John Tokarski, Aberra Fura, Thomas Spires, John Newitt, Vanessa M. Spires, Mary T. Obermeier, Paul A. Elzinga, Marco M. Gottardis, Lata Jayaraman, Gregory D. Vite & Aaron Balog. (2022) The discovery of BMS-737 as a potent, CYP17 lyase-selective inhibitor for the treatment of castration-resistant prostate cancer. Bioorganic & Medicinal Chemistry Letters 75, pages 128951.
Crossref
Crossref
Christian J. Grimme, Mckenna G. Hanson, Louis G. Corcoran & Theresa M. Reineke. (2022) Polycation Architecture Affects Complexation and Delivery of Short Antisense Oligonucleotides: Micelleplexes Outperform Polyplexes. Biomacromolecules 23:8, pages 3257-3271.
Crossref
Crossref
Himanshu Singh, Rajnish Kumar, Avijit Mazumder, Salahuddin, Rupa Mazumder & Mohd. Mustaqeem Abdullah. (2022) Insights into Interactions of Human Cytochrome P450 17A1: A Review. Current Drug Metabolism 23:3, pages 172-187.
Crossref
Crossref
Dan Li, Wenfang Zhou, Jinping Pang, Qin Tang, Bingling Zhong, Chao Shen, Li Xiao & Tingjun Hou. (2019) A magic drug target: Androgen receptor. Medicinal Research Reviews 39:5, pages 1485-1514.
Crossref
Crossref
Charles Dai, Hannelore Heemers & Nima Sharifi. (2017) Androgen Signaling in Prostate Cancer. Cold Spring Harbor Perspectives in Medicine 7:9, pages a030452.
Crossref
Crossref
Julia Gehrig, Silke Kaulfuß, Hubertus Jarry, Felix Bremmer, Mark Stettner, Peter Burfeind & Paul Thelen. (2017) Prospects of estrogen receptor β activation in the treatment of castration-resistant prostate cancer. Oncotarget 8:21, pages 34971-34979.
Crossref
Crossref
Simon Baumgart & Bernard Haendler. (2017) Exploiting Epigenetic Alterations in Prostate Cancer. International Journal of Molecular Sciences 18:5, pages 1017.
Crossref
Crossref
Dejun Bao, Chuandong Cheng, Xiaoqiang Lan, Rong Xing, Zhuo Chen, Hua Zhao, Junyan Sun, Yang Wang, Chaoshi Niu, Bo Zhang & Shengyun Fang. (2017) Regulation of p53wt glioma cell proliferation by androgen receptor-mediated inhibition of small VCP/p97-interacting protein expression. Oncotarget 8:14, pages 23142-23154.
Crossref
Crossref